Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 40
- Registration Number
- NCT06650709
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT06618664
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 460
- Registration Number
- NCT06614192
- Locations
- 🇺🇸
Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 268610, Chicago, Illinois, United States
🇮🇱The Chaim Sheba Medical Center /ID# 267741, Ramat Gan, Tel-Aviv, Israel
🇺🇸Hope And Healing Cancer Services /ID# 268541, Hinsdale, Illinois, United States
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06584071
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06558227
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Target Recruit Count
- 100
- Registration Number
- NCT06557096
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06547385
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Wang Jiayu
- Target Recruit Count
- 60
- Registration Number
- NCT06539559
- Locations
- 🇨🇳
Beijing Chaoyang District San Huan Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital of HuanXing ChaoYang District, Beijing, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Target Recruit Count
- 100
- Registration Number
- NCT06540326
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.